Navigation Links
Evofem Announces Strategic Alliance with WomanCare Global
Date:3/4/2013

SAN DIEGO, March 4, 2013 /PRNewswire/ -- Evofem announced today that it has entered into a strategic alliance with WomanCare Global.  Through this alliance, WomanCare Global will provide sales, marketing and global distribution for a selection of Evofem's products, including Softcup™ and Amphora®.  Additionally, Saundra Pelletier , founding CEO of WomanCare Global, has been named the new CEO of Evofem Inc.

(Logo: http://photos.prnewswire.com/prnh/20130304/CG70327LOGO)

Amphora, a vaginal gel approved by the FDA in 2004 as a lubricant, is currently undergoing the largest global clinical trial to date of a non-hormonal contraceptive vaginal gel. Through various studies, Amphora has shown potential to be effective in protecting against sexually transmitted infections (STIs) including HIV.  Softcup is a personal care alternative to tampons and sanitary pads that can be worn for up to 12 hours.  It's body-friendly, in both disposable and reusable options, with no drying cotton or rayon fibers and no link to Toxic Shock Syndrome (TSS).   

"Our strategic alliance with WomanCare Global is a momentous achievement for Evofem," said Joseph Pike , Evofem LLC's Chief Executive Officer. "Having developed a distribution supply chain into over 100 countries, WomanCare Global operates as a sustainable not-for-profit that will allow us to provide our products and services to women and girls throughout the world, especially to those who live in areas where their reproductive healthcare needs are underserved." 

"We are so pleased to partner with Evofem to create global access to Softcup and contribute to the commercialization plans for Amphora," said WomanCare Global CEO Saundra Pelletier .  "These exciting reproductive health products offer women and girls with an innovative, new contraceptive choice and a safe way to manage their menses."

About Evofem
Evofem LLC is a privately held company that brings advanced prescription and consumer products to global markets addressing the unmet needs of women, men and families. Through its subsidiaries, Evofem Inc. and Cosmederm Bioscience, Evofem discovers, develops and commercializes prescription and over-the-counter products, in the areas of feminine care, contraception, dermatology, pain management, and the prevention of sexually transmitted infections, including HIV/AIDs. Evofem was founded in 2000 and is based in San Diego, California.

About WomanCare Global
Meeting the vast unmet demand for family planning and enabling women to choose whether and when they'll have children requires investing in cost-effective, innovative approaches. WomanCare Global's mission is to provide affordable access to high-quality reproductive health products for women and girls around the world through a sustainable supply chain, empowering them to make and act on safe choices.  WomanCare Global applies industry-based expertise to effectively address the entire supply chain ─ from manufacturing through the timely, reliable delivery of high-quality products and care. This total-market approach positions WomanCare Global strongly for large-scale, sustainable impact.


'/>"/>
SOURCE Evofem
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
2. Hill-Rom Announces Second Quarter 2013 Dividend
3. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
4. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
5. PDL BioPharma Announces Fourth Quarter and Full Year 2012 Financial Results
6. Hospira Announces Executive Changes
7. Citiustech Announces Launch of Bi-Clinical Cloud and App-Based Architecture
8. DMH International Announces FDA Approval of TouchPACS
9. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
10. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
11. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... Gainesville, FL (PRWEB) , ... April 26, 2017 ... ... health and human performance, is proud to announce that it has received 510(k) ... cutting-edge technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
Breaking Medicine News(10 mins):